Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
FDA grants Priority Review to Biogen's ALS therapy
10:21am, Tuesday, 26'th Jul 2022
Biogen Inc. BIIB, +1.34% said Tuesdsay that its experimental treatment for a type of amyotrophic lateral sclerosis (ALS), which is often referred to as Lou Gehrig's disease, has been granted Priority
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
10:20am, Tuesday, 26'th Jul 2022 Zacks Investment Research
Smart Beta ETF report for PBE
Biogen Inc. (BIIB) Upgraded to Buy: What Does It Mean for the Stock?
04:00pm, Monday, 25'th Jul 2022 Zacks Investment Research
Biogen Inc. (BIIB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BIIB vs. ILMN: Which Stock Should Value Investors Buy Now?
03:40pm, Monday, 25'th Jul 2022 Zacks Investment Research
BIIB vs. ILMN: Which Stock Is the Better Value Option?
BIIB vs. ILMN: Which Stock Should Value Investors Buy Now?
01:56pm, Monday, 25'th Jul 2022
BIIB vs. ILMN: Which Stock Is the Better Value Option?
Biogen Inc. (BIIB) Upgraded to Buy: What Does It Mean for the Stock?
01:56pm, Monday, 25'th Jul 2022
Biogen Inc. (BIIB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Biogen tops Q2 2022 earnings and revenue estimates
02:18am, Sunday, 24'th Jul 2022
Biogen Inc (NASDAQ: BIIB) has announced a Q2 2002 revenue of $2.589 billion. GAAP net income was $1.058 billion or $7.24 per diluted share, and non-GAAP net income was $767 million or earnings of $5.2
2nd-Quarter Earnings Results Could Impact Drug Company Shares
04:58pm, Friday, 22'nd Jul 2022
The second-quarter earnings season is upon us, and the news coming out of several members of Big Pharma could potentially shake up their share prices. Beyond that, several unknowns could impact top-ti
With All Eyes On Lecanemab Read Out In Alzheimer's, Uncertainty Overshadows Biogen's Q2 Beat
07:44pm, Thursday, 21'st Jul 2022 Benzinga
Yesterday, Biogen Inc (NASDAQ: BIIB) reported Q2 earnings. Needham writes that while operational performance looked good, uncertainty looms over the company's growth potential.
Lecanemab Phase 3
Ionis (IONS) Partner Wraps Up Cardiovascular Study Enrollment
02:40pm, Thursday, 21'st Jul 2022 Zacks Investment Research
Ionis' (IONS) partner, Novartis completes enrolling patients in a phase III study on pelacarsen for treating cardiovascular disease due to elevated Lp(a) levels. Data from this study is expected in 20
Tesla to $1,175? Here Are 5 Other Price Target Changes for Thursday
11:20am, Thursday, 21'st Jul 2022 Benzinga
Mizuho raised Tesla, Inc. (NASDAQ: TSLA) price target from $1,150 to $1,175. However, Mizuho analyst Vijay Rakesh maintained a Buy rating on the stock. Tesla shares rose 3.3% to $766.88 in pre-mark
Why Baker Hughes Shares Dropped 8%; Here Are 64 Biggest Movers From Yesterday
08:40am, Thursday, 21'st Jul 2022 Benzinga
Gainers
Pagaya Technologies Ltd. (NASDAQ: PGY) shares climbed 129.6% to close at $6.20 on Wednesday. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022.
Direct Digital Ho
Biogen Reveals $900M Settlement In Whistleblower's MS Drug Kickbacks Lawsuit Days Before Trial
06:15am, Thursday, 21'st Jul 2022 Benzinga
Biogen, Inc. (NASDAQ: BIIB) disclosed in its second-quarter earnings report that it recorded $900 million related to a settlement agreement to resolve previously disclosed "qui tam" litigation rel
Nasdaq leads stocks to finish higher as upbeat tech earnings boost investors confidence
08:21pm, Wednesday, 20'th Jul 2022 MarketWatch
U.S. stock indexes were higher Wednesday, as investors await more corporate earnings, with Tesla due to report after the market closes.
Biogen (BIIB) Q2 2022 Earnings Call Transcript
07:00pm, Wednesday, 20'th Jul 2022 The Motley Fool
BIIB earnings call for the period ending June 30, 2022.
